atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate...

Mon, Mar 17

Q4 #Earnings highlights: Strong financial position following successful capital raise, with two Phase 2 trials underway & large Phase 2b results expected mid-2025. 🔗 https://t.co/PZunpTuL35 #MentalHealth

12485

- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical...

Discover